In addition, due to statins, ezetimibe, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, circulating concentrations of low-density lipoprotein (LDL)-cholesterol are drastically reduced in patients at high cardiovascular risk, which lowers the contribution of LDL-cholesterol to ASCVD progression. Here, PCSK9 is linked to atherosclerosis.